CompletedNot Applicable

EMG of Gait Under Dual-Task in Parkinson Desease

Spain30 participantsStarted 2026-03-15

Plain-language summary

In this observational study embedded within a randomized controlled trial, the investigators aim to characterize the activation patterns of the tibialis anterior and medial gastrocnemius muscles in the more rigid leg of patients with Parkinson's disease when performing walking tasks under dual cognitive-task conditions, which are known to increase the risk of falls in this population. To this end, a control group without neurological disorders and with comparable sociodemographic characteristics will also be assessed. The study seeks to determine whether significant changes occur in forward and backward gait as a function of the dual-task condition.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ability to walk independently for at least 5 meters, both forward and backward, without the need for assistive devices or assistance from another person. * Diagnosis of idiopathic Parkinson's disease made by a neurologist at Hospital Virgen Macarena. * Hoehn and Yahr stage I-III. * Being in the "ON" phase of antiparkinsonian medication during the assessment (approximately one hour after intake, when the pharmacokinetic curve of levodopa reaches its peak). Exclusion Criteria: * Presence of symptomatic musculoskeletal disorders affecting the lower limbs (LL) (relevant orthopedic surgery or leg length discrepancy \> 1 cm), or other neurological conditions (stroke, neuropathies, etc.) that independently affect gait. * Balance disorders due to other causes (vestibulopathy, severe orthostatic hypotension, etc.). * Decompensated systemic diseases (cardiac disease, COPD, uncontrolled diabetes mellitus, etc.). * Uncorrected visual impairments that may affect gait performance. * Previous treatment with deep brain stimulation.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

%MIVC

Timeframe: Baseline (Day 1)

Trial details

NCT IDNCT07584343

SponsorUniversity of Cadiz

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-30

View on ClinicalTrials.gov More Parkinson Disease (PD) trials